In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.